• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

    6/15/25 4:00:00 AM ET
    $ILMN
    $INCY
    $QGEN
    Medical Specialities
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ILMN alert in real time by email
    • QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies
    • Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs
    • Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples
    • Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline

    QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) and Incyte (NASDAQ:INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET).

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615075973/en/

    Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies.

    The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ:ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions.

    Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood.

    Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes.

    "Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs."

    "Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once," said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. "This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes."

    About Mutations in Calreticulin (mutCALR)

    Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs),i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood cells.ii,iii Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases.i,ii

    About QIAGEN

    QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit https://www.qiagen.com.

    QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics.

    For more information about QIAGEN's efforts in precision medicine please visit https://www.qiagen.com/us/clp/partnering-for-precision-diagnostics.

    About Incyte

    A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

    For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

    QIAGEN Forward-Looking Statement

    Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

    Incyte Forward-Looking Statements

    Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements.

    These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements.

    Source: QIAGEN N.V.

    Category: Precision Medicine

    i Raghavan, M., Wijeyesakere S.J., Peters L.R., Del Cid N. (2013) Calreticulin in the immune system: ins and outs. Trends in Immunology, 34(1):13-21. Link to source (https://www.cell.com/trends/immunology/abstract/S1471-4906(12)00131-7?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1471490612001317%3Fshowall%3Dtrue)

    ii Nangalia J. Massie C.E., Baxter E.J., Nice F.L., et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Link to source (https://www.nejm.org/doi/10.1056/NEJMoa1312542?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov)

    iii Klampfl T., Gisslinger, H., Harutyunyan A.S., et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25):2379-2390. Link to source (https://www.nejm.org/doi/10.1056/NEJMoa1311347?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov)

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250615075973/en/

    Contacts QIAGEN:

    Investor Relations

    [email protected]

    Public Relations

    [email protected]

    Contacts Incyte:

    M
    edia

    [email protected]

    Investors

    [email protected]

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ILMN
    $INCY
    $QGEN

    CompanyDatePrice TargetRatingAnalyst
    Qiagen N.V.
    $QGEN
    6/24/2025$55.00Overweight
    Barclays
    Incyte Corp.
    $INCY
    6/16/2025$107.00Hold → Buy
    Stifel
    Qiagen N.V.
    $QGEN
    4/4/2025Buy → Neutral
    Redburn Atlantic
    Incyte Corp.
    $INCY
    3/18/2025Buy → Neutral
    Guggenheim
    Incyte Corp.
    $INCY
    3/18/2025Outperform → Mkt Perform
    William Blair
    Illumina Inc.
    $ILMN
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    Illumina Inc.
    $ILMN
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    Qiagen N.V.
    $QGEN
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $ILMN
    $INCY
    $QGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Human Resources Swain Paula J covered exercise/tax liability with 6,285 shares, decreasing direct ownership by 6% to 101,059 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:56:19 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Principal Accounting Officer Tray Thomas covered exercise/tax liability with 897 shares, decreasing direct ownership by 4% to 21,106 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:48:58 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP & Chief Medical Officer Stein Steven H covered exercise/tax liability with 12,714 shares, decreasing direct ownership by 10% to 112,418 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/7/25 4:48:25 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ILMN
    $INCY
    $QGEN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ILMN
    $INCY
    $QGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • iRhythm Technologies Announces Board Member Retirements and New Director Appointments

      SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br

      7/7/25 8:30:00 AM ET
      $ABSI
      $ATEC
      $ILMN
      $IRTC
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Medical/Dental Instruments
      Medical Specialities
    • Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      Incyte Corporation (NASDAQ:INCY) announced today equity inducement awards grants to Bill Meury in connection with his appointment as the Company's new President and Chief Executive Officer. The awards are made pursuant to the Company's 2024 Inducement Stock Incentive Plan and were approved by the compensation committee of the Company's Board of Directors as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). As an inducement material to his employment and in lieu of the annual equity awards the Company typically grants in July of each year, Mr. Meury received, with a grant and vesting commencement date of

      7/2/25 4:30:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

      Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate G

      6/26/25 1:16:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ILMN
    $INCY
    $QGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on Qiagen with a new price target

      Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00

      6/24/25 8:09:28 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Incyte upgraded by Stifel with a new price target

      Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

      6/16/25 7:42:04 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Qiagen downgraded by Redburn Atlantic

      Redburn Atlantic downgraded Qiagen from Buy to Neutral

      4/4/25 8:39:19 AM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ILMN
    $INCY
    $QGEN
    SEC Filings

    See more
    • SEC Form 144 filed by Incyte Corp.

      144 - INCYTE CORP (0000879169) (Subject)

      7/3/25 2:46:56 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 filed by Incyte Corp.

      S-8 - INCYTE CORP (0000879169) (Filer)

      7/2/25 4:00:42 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 6-K filed by Qiagen N.V.

      6-K - QIAGEN N.V. (0001015820) (Filer)

      6/27/25 6:35:29 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ILMN
    $INCY
    $QGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:20:13 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      5/14/25 4:18:28 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

      4 - ILLUMINA, INC. (0001110803) (Issuer)

      2/26/24 8:57:29 AM ET
      $ILMN
      Medical Specialities
      Health Care

    $ILMN
    $INCY
    $QGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

      Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief Investment Officer of Corvex Management, will join the Board of Directors on March 28, 2025. Stephen MacMillan, Chairman, President, and CEO of Hologic, who joined the Illumina Board in June 2023, has decided to retire from the board in preparation for the company

      3/25/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Neogen Announces the Appointment of New Board Member

      LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

      10/1/24 8:45:00 AM ET
      $NEOG
      $QGEN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ILMN
    $INCY
    $QGEN
    Financials

    Live finance-specific insights

    See more
    • QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

      Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate G

      6/26/25 1:16:00 PM ET
      $QGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

      Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI

      6/18/25 9:00:00 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ILMN
    $INCY
    $QGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      12/6/24 10:11:24 AM ET
      $ILMN
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Illumina Inc.

      SC 13G - ILLUMINA, INC. (0001110803) (Subject)

      12/5/24 7:27:01 PM ET
      $ILMN
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Illumina Inc.

      SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

      11/12/24 3:59:44 PM ET
      $ILMN
      Medical Specialities
      Health Care